DYADIC INTERNATIONAL INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
DYADIC INTERNATIONAL INC (DYAI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 3.90% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-12
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.90%.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 0.55%.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.40%, a 4.35% decline from fiscal 2024.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.60%.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 1.72%, a 31.20% decline from fiscal 2019.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 2.50%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.90% 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 4.40% 10-K · filed 2026-03-25 | |||
| 2025-09-30 | 4.40% 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 4.40% 10-Q · filed 2025-08-13 | |||
| 2024-12-31 | 4.60% 10-K · filed 2026-03-25 | |||
| 2024-09-30 | 4.61% 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | 4.61% 10-Q · filed 2024-08-13 | |||
| 2021-09-30 | 0.85% 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | 0.55% 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | 0.55% 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 1.72% 10-K · filed 2021-03-30 | |||
| 2019-12-31 | 2.50% 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |